Abstract
The need to develop new therapeutic targets for the treatment of neuropsychiatric disorders is a consensus in the scientific literature. Endocannabinoids (eCBs) have been proposed as a possible target, and studies by our group have shown the therapeutic potential of drugs that act on these atypical neurotransmitters in anxiety disorders, depression, psychosis, Parkinson's and neurodegener…